Bicalutamide and flutamide, each in combination with luteinizing hormone-releasing hormone analogs, in advanced prostate cancer: Exploratory analysis of impact of extent of disease by bone scan on outcome

Prostate Journal

Volumn 2, Issue 3, 2000, Pages 137-145

  Soloway, Mark S ^a   Schellhammer, Paul F ^b   Sharifi, Rooholloh ^c   Block, Norman L ^d   Venner, Peter M ^e   Lynn Patterson, A ^f   Sarosdy, Michael F ^g   Vogelzang, Nicholas J ^h   Schellenger, Julie ^h   Kolvenbag, Geert J C M ^h  

^a UNIVERSITY OF MIAMI MILLER SCHOOL OF MEDICINE   (United States)

^b EASTERN VIRGINIA MEDICAL SCHOOL   (United States)

^c UNIVERSITY OF ILLINOIS AT CHICAGO   (United States)

^d CROSS CANCER INSTITUTE   (Canada)

^e UNIVERSITY OF TENNESSEE   (United States)

^f UNIVERSITY OF TEXAS HEALTH SCIENCE CENTER AT SAN ANTONIO   (United States)

^g UNIVERSITY OF CHICAGO MEDICAL CENTER   (United States)

^h ASTRAZENECA   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

BICALUTAMIDE; FLUTAMIDE; GONADORELIN DERIVATIVE; GOSERELIN; LEUPRORELIN;

ADULT; ADVANCED CANCER; AGED; ARTICLE; BONE SCINTISCANNING; CANCER SURVIVAL; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DISEASE COURSE; DISEASE SEVERITY; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; FOLLOW UP; HUMAN; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; PROSTATE CANCER; RANDOMIZED CONTROLLED TRIAL; TREATMENT OUTCOME;

EID: 0033869637     PISSN: 10955100     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1525-1411.2000.23003.x     Document Type: Article

References (22)

1. 1 Debruyne FMJ & Dijkman GA. (1995) Advances and trends in hormonal therapy for advanced prostate cancer. Eur. Urol. 28: 177 188.
2. 2 Labrie F, DuPont A, Belanger A, et al. (1983) New approach in the treatment of prostate cancer: complete instead of partial withdrawal of androgens. Prostate 4: 579 594.
3. 3 Bracci U & Di Silverio F. (1977) Role of cyproterone acetate in urology. In: Martini L, Motta M (eds). Androgens and Antiandrogens. Raven Press, New York, pp. 333 339.
4. 4 Labrie F, Dupont A, Belanger A. (1985) Complete androgen blockade for the treatment of prostate cancer. In: DeVita VT, Hellman S, Rosenberg SA (eds). Advances in Onology. Lippincott, Philadelphia, pp. 193 200.
5. 5 Schellhammer P, Sharifi R, Block N, et al. (1995) A controlled trial of bicalutamide versus flutamide, each in combination with luteinizing hormone‐releasing hormone analogue therapy, in patients with advanced prostate cancer. Urology 45: 745 752.
6. 6 Schellhammer PF, Sharifi R, Block NL, et al. (1997) Clinical benefits of bicalutamide compared with flutamide in combined androgen blockade for patients with advanced prostatic carcinoma: final report of a double‐blind, randomized, multicenter trial. Urology 50: 330 336.
7. 7 Crawford ED, Eisenberger MA, McLeod DG, Wilding G, Blumenstein BA. (1997) Comparison of bilateral orchiectomy with or without flutamide for the treatment of patients (PTS) with stage D‐2 adenocarcinoma of the prostate (CaP): results of NCI intergroup study 0105 (SWOG and ECOG). J. Urol. 157 (Suppl 4): 336.
8. 8 Eisenberger MA, Crawford ED, Wolf M, et al. (1994) Prognostic factors in stage D2 prostate cancer; important implications for future trials: results of a cooperative intergroup study (INT 0036). Semin. Oncol. 21: 613 619.
9. 9 Denis LJ, De Moura JLC, Bono A, et al. (1993) Goserelin acetate and flutamide versus bilateral orchiectomy: a phase III EORTC trial (30853). Urology 42: 119 130.
10. 10 Morote J, Vallejo C, Lorente JA, et al. (1995) Final results of complete hormone blockade versus monotherapy in prostatic metastatic cancer: PSA implications. Actas Urol. Esp. 19: 604 610.
11. 11 Labrie, F, Dupont A, Cusan L, Gomez J‐L, Diamond P. (1993) Major advantages of “early” administration of endocrine combination therapy in advanced prostate cancer. Clin. Invest. Med. 16: 493 498.
12. 12 Crawford ED, Eisenberger MA, McLeod DG, et al. (1989) A controlled trial of leuprolide with and without flutamide in prostatic carcinoma. N. Engl. J. Med. 321: 419 424.
13. 13 Chodak GW, Vogelzang NJ, Caplan RJ, Soloway MS, Smith JA. (1991) Independent prognostic factors in patients with metastatic (stage D2) prostate cancer: the Zoladex Study Group. JAMA 265: 618 621.
14. 14 Schellhammer P, Sharifi R, Block N, et al. (1996) Maximal androgen blockade for patients with metastatic prostate cancer: outcome of a controlled trial of bicalutamide versus flutamide, each in combination with luteinizing hormone‐releasing hormone analogue therapy. Urology 47 (Suppl 1A): 54 60.
15. 15 Schellhammer PF, Sharifi R, Block NL, et al. (1996) A controlled trial of bicalutamide versus flutamide, each in combination with luteinizing hormone‐releasing hormone analogue therapy, in patients with advanced prostate carcinoma. Analysis of time to progression. Cancer 78: 2164 2169. DOI: 10.1002/(sici)1097-0142(19961115)78:10<2164::aid-cncr18>3.0.co;2-x
16. 16 McLeod D. (1997) Tolerability of non‐steroidal antiandrogens. Oncologist 2: 18 27.
17. 17 Soloway MS, Hardeman SW, Hickey D, et al. (1988) Stratification of patients with metastatic prostate cancer based on extent of disease on initial bone scan. Cancer 61: 195 202.
18. 18 Benson RC. (1993) Total androgen blockade: the United States experience. Eur. Urol. 24 (Suppl 2): 72 76.
19. 19 Jørgensen T, Müller C, Kaalhus O, Danielsen HE, Tveter KJ. (1995) Extent of disease based on initial bone scan: important prognostic predictor for patients with metastatic prostatic cancer: experience from the Scandinavian Prostatic Cancer Group Study No. 2 (SPCG‐2). Eur. Urol. 28: 40 46.
20. 20 Lowe BA & Listrom MB. (1988) Incidental carcinoma of the prostate: an analysis of the predictors of progression. J. Urol. 140: 1340 1344.
21. 21 Pollen JJ. (1982) Whither pelvic lymphadenectomy in prostatic cancer? Prostate 3: 247 252.
22. 22 Crawford ED, DeAntonio EP, Labrie F, Schroder FH, Geller J. (1995) Endocrine therapy of prostate cancer: optimal form and appropriate timing. J. Clin. Endocrinol. Metab. 80: 1062 1065.